Cerebralink Neurotech Consultancy
Neurotechnology Experts
Dr Paul Shotbolt
I studied medicine at Cambridge University and Guy’s and St.Thomas’s Hospitals, qualifying in 1996. I completed all of my psychiatric training at the Maudsley Hospital, obtaining my certificate of completion of training in 2007. I took an academic route through my higher training, working as a research fellow in the Department of Cognitive Neuropsychiatry. I was awarded a Wellcome Translational Training Fellowship in 2007, and between 2007-2010 I was the principal investigator on several neurochemical imaging studies at the PET centre at Imperial College, Hammersmith. In 2010 I took up my current position of Consultant Neuropsychiatrist at the Maudsley Hospital. In 2016 I was appointed to the post of Clinical Senior Lecturer at the Institute of Psychiatry, Psychology and Neuroscience and am Programme Leader for the Clinical Neuropsychiatry MSc Clinically I am interested in the neuropsychiatric aspects of Parkinson’s disease and other movement disorders, including functional neurological disorders (FND). I was a member of the latest NICE Guideline Development Group for Parkinson’s disease. I am the lead for the King’s Health Partners (KHP) FND workstream, which aims to optimise care pathways, training and research for FND. I also have a longstanding medicolegal practice focused on neuropsychiatric aspects of traumatic brain injury. Academically I have a strong interest in development of neurotechnology applications in neuropsychiatric disorders. I am the principal investigator on a study examining impulse control disorders pre- and post-Deep Brain Stimulation (DBS) for PD. Our group is developing personalised biomarker closed-loop DBS applications for neuropsychiatric conditions. I am developing applications of non-invasive techniques such as transcranial magnetic stimulation (TMS) and transcranial temporal interference stimulation (tTIS). I am founding director of the new Maudsley Neurotechnology (MNT) centre. MNT aims to deliver evidence-based neurotechnology treatments for psychiatric disorders.